Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotech company focused on innovative antibody therapies for Inflammatory Bowel Disease or IBD and related immune disorders, Monday announced two poster presentations at Digestive Disease Week or DDW 2025, held from May 3-6 in San Diego, California.
The company presented eight-month follow-up data from its Phase 1 trial of SPY001, a half-life extended a4ß7 antibody. The updated results show SPY001 continues to be well tolerated, has a half-life more than three times longer than vedolizumab based on pharmacokinetic (PK) modeling, and maintains sustained target engagement at expected Phase 2 trough levels. This supports its potential for enhanced induction and long-lasting responses, with maintenance dosing potentially only needed quarterly or twice a year.
Preclinical data also demonstrated that dual inhibition of a4ß7 integrin and TL1A cytokine offers superior efficacy over individual therapies in mouse models of colitis. No drug-drug interactions were observed in non-human primates co-administered SPY001 and SPY002.
Dr. Deanna Nguyen, SVP of Clinical Development at Spyre, noted that the extended follow-up data reinforce the potential for SPY001 to offer best-in-class quarterly or biannual dosing for IBD patients. She added that Spyre plans to evaluate SPY001 both as a standalone therapy and as a combination backbone in its upcoming Phase 2 platform trial in ulcerative colitis, which is scheduled to launch mid-2025.
Both posters are available during the DDW 2025 exhibition. Full session details can be found in the official DDW program.
SYRE is currently trading at $13.97 or 7.58% lower on the Nasdaq Global Select Market.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.